Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 4/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | KCNK2 | O95069 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| R-Fluoxetine SCHEMBL1200433 | 1.00 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL8467346 | 1.00 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL8353 | 1.00 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL33947 | 1.00 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| R-Fluoxetine SCHEMBL3905325 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL7081402 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL8911991 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL17436534 | 0.99 | SLC6A4 (0.97) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL3399076 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL7902048 | 0.99 | SLC6A4 (0.97) | SLC6A4MEN1KMT2ALMNASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141380-A1 | INHIBITORS OF ERK FOR DEVELOPMENTAL DISORDERS OF NEURONAL CONNECTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-05-21 | — | — | US | claimed |
| CN-102292094-A | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | — | 2011-12-21 | — | — | CN | claimed |
| US-10941194-B2 | Methods of diagnosing and treating autism spectrum disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-09 | — | — | US | disclosed |
| US-20180002410-A1 | METHODS OF DIAGNOSING AND TREATING AUTISM SPECTRUM DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-01-04 | — | — | US | disclosed |
| WO-2016118924-A1 | METHODS OF DIAGNOSING AND TREATING AUTISM SPECTRUM DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-07-28 | — | — | WO | disclosed |
| EP-2600862-B1 | INHIBITORS OF ERK FOR DEVELOPMENTAL DISORDERS OF NEURONAL CONNECTIVITY | UNIV CASE WESTERN RESERVE (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20150141380-A1 | INHIBITORS OF ERK FOR DEVELOPMENTAL DISORDERS OF NEURONAL CONNECTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-05-21 | — | — | US | disclosed |
| WO-2014074805-A1 | SELECTIVE TARGETING OF CANCER STEM CELLS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-05-15 | — | — | WO | disclosed |
| EP-2600862-A2 | INHIBITORS OF ERK FOR DEVELOPMENTAL DISORDERS OF NEURONAL CONNECTIVITY | Case Western Reserve University (US) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012019113-A2 | INHIBITORS OF ERK FOR DEVELOPMENTAL DISORDERS OF NEURONAL CONNECTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-02-09 | — | — | WO | disclosed |
| EP-1758600-A4 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MAN SCIENCES LLC (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1691811-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | Sepracor, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1680121-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2006-07-19 | — | — | EP | disclosed |
| US-7005138-B2 | Method of systematically delivering SSRIs | DURAMED PHARMACEUTICALS, INC. (US) | 2006-02-28 | — | — | US | disclosed |
| WO-2005120523-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MANAGEMENT SCIENCES, LLC (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| EP-1465563-A1 | METHOD OF SYSTEMICALLY DELIVERING SSRIs | Duramed Pharmaceuticals, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030133977-A1 | Method of systemically delivering SSRIs | TEVA WOMEN'S HEALTH, INC. | 2003-07-17 | — | — | US | disclosed |
| WO-2003055424-A1 | METHOD OF SYSTEMICALLY DELIVERING SSRIs | DURAMED PHARMACEUTICALS, INC. (US) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030133977-A1 | Method of systemically delivering SSRIs | TPH1, HTR1D, HTR5A | SLC6A4 6/4885MEN1 835/4885KMT2A 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.